Printer Friendly

Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement.

M2 PHARMA-October 4, 2018-Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement

(C)2018 M2 COMMUNICATIONS

- Japan-based drug discovery solutions provider Axcelead Drug Discovery Partners, Inc. and Ireland-based ERS Genomics Ltd. have inked a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics' CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering, the companies said.

ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology.

Axcelead is an integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded some portion of the drug discovery research department of Takeda Pharmaceutical company Ltd.

Axcelead started its business in July of 2017 and offers a comprehensive list of drug discovery services in a broad range of therapeutic areas.

Dr. Emmanuelle Charpentier's research unveiled the key components and mechanisms of the CRISPR/Cas9 system that led to the landmark publication with Jennifer Doudna (Jinek, Chylinski et al., 2012), which laid the foundation for the use of CRISPR/Cas9 as a highly versatile and precise genome editing tool.

Axcelead has all the functions related to non-clinical drug discovery research and is also able to draw on the scientific powerhouse of our personnel with expertise, deep knowledge and experience in a range of therapeutic areas through their previous work at Takeda.

The company offers a one research services with a set of capabilities to meet a range of customer needs to bridge basic and applied clinical research, from exploratory research to optimising compounds.

Axcelead is based in Fujisawa, Japan.

ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier.

Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:9JAPA
Date:Oct 4, 2018
Words:355
Previous Article:CANbridge Pharmaceutical Submits New Drug Application for Nerlynx in China.
Next Article:Alnylam Submits Clinical Trial Authorization Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin...
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters